These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32387683)

  • 1. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
    Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
    Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
    Garon EB; Visseren-Grul C; Rizzo MT; Puri T; Chenji S; Reck M
    Front Oncol; 2023; 13():1247879. PubMed ID: 37731641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment.
    Takahara Y; Abe R; Nagae S; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
    Thorac Cancer; 2023 Dec; 14(36):3549-3555. PubMed ID: 37964501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer.
    Hamai K; Katsura R; Miyake S; Fujita S; Tada S; Hirakawa T; Ueno S; Tanimoto T; Ishikawa N
    Cancer Control; 2024; 31():10732748241274615. PubMed ID: 39120923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
    Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
    Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Harada D; Takata K; Mori S; Kozuki T; Takechi Y; Moriki S; Asakura Y; Ohno T; Nogami N
    Anticancer Res; 2019 Sep; 39(9):4987-4993. PubMed ID: 31519605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
    Zhou GW; Xiong Y; Chen S; Xia F; Li Q; Hu J
    Medicine (Baltimore); 2016 Aug; 95(35):e4611. PubMed ID: 27583876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
    Clin Lung Cancer; 2022 Nov; 23(7):e400-e404. PubMed ID: 35863963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of using history of immune checkpoint inhibitor therapy for neutropenia caused by combination therapy of ramucirumab and docetaxel.
    Ohno H; Mano S; Katagiri N; Oguri R; Miyazaki K; Ito K; Sekiya Y; Inoue K; Masuda A; Tsuzuku A; Asano F; Hirashita T; Hayashi T
    Pharmazie; 2022 Sep; 77(7):248-254. PubMed ID: 36199179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
    Tanizaki S; Matsumoto K; Tamiya A; Taniguchi Y; Matsuda Y; Uchida J; Ueno K; Kawachi H; Tamiya M; Yanase T; Suzuki H; Okishio K
    Eur J Clin Pharmacol; 2023 Apr; 79(4):503-511. PubMed ID: 36773042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
    Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
    Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
    Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
    Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JC; Bajars M; Ruisi M; Manitz J; Barlesi F
    Lung Cancer; 2021 Apr; 154():92-98. PubMed ID: 33636453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
    Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.